Arvinas gets grant for bifunctional compounds for modulating Tau protein
Pharmaceutical Technology
APRIL 22, 2024
Discover Arvinas Inc's groundbreaking patent for compounds targeting tau protein degradation, offering hope for Alzheimer's and other neurodegenerative diseases. Learn about the promising results and potential therapeutic value of this innovative treatment.
Let's personalize your content